Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
Sponsor: Zai Lab (Shanghai) Co., Ltd.
Summary
A Multicenter, Double-blinded, Randomized, Placebo-controlled Phase 3 Study of ZL-1109 in Chinese Participants with Thyroid Eye Disease (TED)
Official title: A Multicenter, Double-blinded, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ZL-1109 in Chinese Participants With Thyroid Eye Disease (TED)
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
99
Start Date
2025-12-05
Completion Date
2028-01-29
Last Updated
2025-12-29
Healthy Volunteers
No
Conditions
Interventions
ZL-1109 (VRDN-003)
ZL-1109 subcutaneous injection
Placebo
Matching placebo subcutaneous injection
Locations (27)
Site01006
Beijing, China
Site01009
Beijing, China
Site01010
Beijing, China
Site01029
Bengbu, China
Site01020
Changsha, China
Site01022
Chengdu, China
Site01031
Chongqing, China
Site01011
Dalian, China
Site01008
Foshan, China
Site01004
Fuzhou, China
Site01007
Guangzhou, China
Site01027
Guiyang, China
Site01018
Hangzhou, China
Site01002
Hefei, China
Site01024
Jinan, China
Site01005
Luoyang, China
Site01017
Nanchang, China
Site01001
Shanghai, China
Site01012
Shenyang, China
Site01023
Taiyuan, China
Site01013
Tianjin, China
Site01016
Wuxi, China
Site01028
Xi'an, China
Site01025
Xuzhou, China
Site01026
Yangzhou, China
Site01019
Zhengzhou, China
Site01030
Zhengzhou, China